122 related articles for article (PubMed ID: 38753354)
21. Wild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosis.
Kreft A; Springer E; Lipka DB; Kirkpatrick CJ
Acta Haematol; 2009; 122(1):36-8. PubMed ID: 19713696
[TBL] [Abstract][Full Text] [Related]
22. Cyclic severe elevated procalcitonin serum levels in a patient with post polycythemic myelofibrosis carrying a V617F-JAK2 mutation.
Stölzel F; Babatz J; Thiede C; Siegert G; Illmer T; Ehninger G; Schaich M
Ann Hematol; 2008 Dec; 87(12):1021-2. PubMed ID: 18548249
[No Abstract] [Full Text] [Related]
23. The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.
Rudzki Z; Sacha T; Stój A; Czekalska S; Wójcik M; Skotnicki AB; Grabowska B; Zduńczyk A; Okoń K; Stachura J
Int J Hematol; 2007 Aug; 86(2):130-6. PubMed ID: 17875526
[TBL] [Abstract][Full Text] [Related]
24. The Temporal Sequence and the Differences in Somatic Mutation Acquisition Determines Clinical Behaviors of JAK2-Positive Myeloproliferative Neoplasms.
Byun JM; Song S; Koh Y; Yoon SS; Kim D
Anticancer Res; 2019 Nov; 39(11):6273-6282. PubMed ID: 31704857
[TBL] [Abstract][Full Text] [Related]
25. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
Shide K; Shimoda HK; Kumano T; Karube K; Kameda T; Takenaka K; Oku S; Abe H; Katayose KS; Kubuki Y; Kusumoto K; Hasuike S; Tahara Y; Nagata K; Matsuda T; Ohshima K; Harada M; Shimoda K
Leukemia; 2008 Jan; 22(1):87-95. PubMed ID: 18033315
[TBL] [Abstract][Full Text] [Related]
26. Possibility of transformation of primary myelofibrosis to ALL without JAK2V617F mutation.
Jurisic V; Pavlovic S; Colovic N; Colovic M
Med Oncol; 2013 Mar; 30(1):398. PubMed ID: 23297051
[No Abstract] [Full Text] [Related]
27. Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia.
Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Ruiz-Delgado GJ; Rosillo C; Camoriano JK
Am J Hematol; 2007 May; 82(5):400-2. PubMed ID: 17133423
[TBL] [Abstract][Full Text] [Related]
28. The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.
Ikeda K; Ueda K; Sano T; Ogawa K; Ikezoe T; Hashimoto Y; Morishita S; Komatsu N; Ohto H; Takeishi Y
Intern Med; 2017; 56(13):1705-1710. PubMed ID: 28674362
[TBL] [Abstract][Full Text] [Related]
29. Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515 L-positive myelofibrosis.
Schulze S; Stengel R; Jaekel N; Wang SY; Franke GN; Roskos M; Schneider M; Niederwieser D; Al-Ali HK
Genes Chromosomes Cancer; 2019 Nov; 58(11):747-755. PubMed ID: 31135094
[TBL] [Abstract][Full Text] [Related]
30. Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis.
Tognon R; Gasparotto EP; Neves RP; Nunes NS; Ferreira AF; Palma PV; Kashima S; Covas DT; Santana M; Souto EX; Zanichelli MA; Simões BP; de Souza AM; Castro FA
J Hematol Oncol; 2012 Feb; 5():2. PubMed ID: 22300941
[TBL] [Abstract][Full Text] [Related]
31. A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis.
Bellosillo B; Martínez-Avilés L; Gimeno E; Florensa L; Longarón R; Navarro G; Salar A; Espinet B; Solé F; Serrano S; Besses C
Leukemia; 2007 Jun; 21(6):1331-2. PubMed ID: 17361221
[No Abstract] [Full Text] [Related]
32. Mesenchymal stem cells from JAK2(V617F) mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele.
Pieri L; Guglielmelli P; Bogani C; Bosi A; Vannucchi AM;
Leuk Res; 2008 Mar; 32(3):516-7. PubMed ID: 17706283
[No Abstract] [Full Text] [Related]
33. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
34. Recurrent chromosomal aberration at 12q15 in chronic idiopathic myelofibrosis with or without JAK2(V617F) mutation.
Ohyashiki K; Tauchi T; Kuroda M; Kodama A; Ohyashiki JH
Leukemia; 2007 Jul; 21(7):1578-80. PubMed ID: 17443223
[No Abstract] [Full Text] [Related]
35. Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis.
Masarova L; Wang W; Newberry KJ; Kantarjian H; Verstovsek S
Blood; 2016 Aug; 128(6):877-80. PubMed ID: 27325105
[No Abstract] [Full Text] [Related]
36. JAK2-V617F-mutated myeloproliferative neoplasms reveal different allele burden within hematopoietic cell lineages: a microdissection study of bone marrow trephine biopsies.
Kreft A; Kindler T; Springer E; Kirkpatrick CJ
Virchows Arch; 2011 Nov; 459(5):521-7. PubMed ID: 22006129
[TBL] [Abstract][Full Text] [Related]
37. Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis.
Bornhäuser M; Mohr B; Oelschlaegel U; Bornhäuser P; Jacki S; Ehninger G; Thiede C
Leukemia; 2007 Aug; 21(8):1824-6. PubMed ID: 17476275
[No Abstract] [Full Text] [Related]
38. A case of myeloid sarcoma with correlation to JAK2V617F mutation, complicated by myelofibrosis and secondary acute myeloid leukemia.
Yoshiki Y; Asai T; Ichikawa M; Hangaishi A; Ota S; Imai Y; Takahashi T; Kurokawa M
Intern Med; 2011; 50(21):2649-52. PubMed ID: 22041374
[TBL] [Abstract][Full Text] [Related]
39. JAK2 V617F mutation positive primary myelofibrosis with concomitant t(9;11;22)(q34;p15;q11.2) but no BCR/ABL fusion.
Au WY; Wan TS; Ma ES
Int J Hematol; 2013 Mar; 97(3):435-7. PubMed ID: 23389763
[No Abstract] [Full Text] [Related]
40. Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients.
Stein BL; Williams DM; Rogers O; Isaacs MA; Spivak JL; Moliterno AR
Exp Hematol; 2011 Jan; 39(1):95-101. PubMed ID: 20888389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
